Icotrokinra, the first oral IL-23 inhibitor, delivers biologic-like efficacy without the need for injections
It also depends on how the numbers are measuredclinical trials report weight loss using different estimands (essentially, different ways of calculating average results), which is why youll sometimes see slightly different percentages for the same study
At the top studied dose of 4.5 mg , cagrilintide produced a mean weight reduction of roughly 10.8% at 26 weeks , versus about 3.0% with placebo
Treatment protocols for KLOW are determined by the prescribing clinician based on an individual patients health history, goals, and clinical assessment
It also lowered the height of internal organs, caecal short-chain fatty acid, and ileal villus